Patent estate

Nippon Shinyaku — Patent Portfolio

1 drug with active patents · 2 active patents · 0 expired · 0 biologics with BPCIA exclusivity

AI-enriched 2/2 patents with grounded plain-English summaries · sourced from FDA Orange Book + Purple Book · updated 2026-05-18

Loss of exclusivity calendar · next 12 years

Drugs facing US patent or BPCIA biologic exclusivity loss per year. Click any year to see the broader cliff calendar for the industry.

1 2031 1 2034

Patent estate by drug

Viltepso (VILTOLARSEN)

Cliff 2031 · 5y
Method of Use 1 Composition of Matter 1
  • US10870676 Vuln 68 2031-08-31
    This patent protects an oligomer and pharmaceutical composition that cause skipping of the 53rd exon in the human dystrophin gene.
  • US9079934 Vuln 4 2034-04-03
    This patent protects an oligomer that causes skipping of the 53rd exon in the human dystrophin gene and a pharmaceutical composition that achieves this with high efficiency.

Patent classification breakdown · active patents

By US patent type. Method-of-use patents are most vulnerable to design-around; composition-of-matter patents are the strongest protection.

  • Method of Use 1 patent
  • Composition of Matter 1 patent

Sources

  • FDA Orange Book — small-molecule patents listed against approved NDAs.
  • FDA Purple Book — biologic BPCIA 12-year reference product exclusivity.
  • USPTO Patent Public Search — title, abstract, claim text grounding.
  • AI summaries generated by Drug Landscape, grounded in source claim text.

Patent term extensions (PTR, SPC, pediatric exclusivity) may shift effective expiry. Not legal advice.

Track Nippon Shinyaku's patent estate

Daily alerts when vulnerability scores shift, patents expire, or IPRs are filed. Free tier: 3 watches. Pro tier (£199/mo): 50 watches + daily AI Pharma IP Brief.

↓ CSV export